慢性肾脏病肾脏保护作用的新兴药物靶点
本综述描述了GLP1RA、ASi、sGC激动剂和ERA等新药如何在CKD患者中降低心肾风险;长效GLP1RA已推荐用于CKD合并2型糖尿病患者的血糖控制,FLOW试验因疗效提前终止;ASi在ACEI/ARB基础上提供额外获益,sGC激动剂减少白蛋白尿,ERA通过血流动力学和抗纤维化机制发挥作用。
要点
- 长效GLP1RA已推荐用于CKD合并2型糖尿病患者的血糖控制,FLOW试验因疗效提前终止。
- ASi在ACEI/ARB基础上提供额外获益,正在开展更大规模试验评估延缓CKD进展的效果。
- sGC激动剂靶向一氧化氮生物利用度减少白蛋白尿,ERA通过血流动力学和抗纤维化机制发挥作用。
核心结论
- 新兴疗法如GLP1RA、ASi、sGC激动剂和ERA有望进一步延缓CKD进展并改善患者预后。
研究设计与样本
- 本综述汇总了支持CKD新兴疗法的临床证据,涵盖GLP1RA及其他肠促胰素疗法、ASi、ERA、sGC激动剂和抗炎药物。
主要发现
- 长效GLP1RA已推荐用于CKD合并2型糖尿病患者的血糖控制,FLOW肾脏结局试验因疗效提前终止。
- 新兴临床试验证据支持ASi在ACEI或ARB基础上提供额外获益。
- sGC激动剂靶向一氧化氮生物利用度从而减少白蛋白尿。
- ERA通过血流动力学和抗纤维化机制发挥作用,针对CKD发展的共同最终通路。
关键数值与推荐
- 长效GLP1RA已推荐用于CKD合并2型糖尿病患者的血糖控制。
- FLOW试验因疗效提前终止。
- ASi在ACEI或ARB基础上提供额外获益。
临床怎么用
- GLP1RA已可用于CKD合并2型糖尿病患者的血糖管理并可能降低终末期肾病风险。
- ASi、sGC激动剂和ERA仍需更大规模临床试验验证其延缓CKD进展的疗效。
局限性
- GLP1RA的肾脏保护机制尚待进一步研究阐明。
- ASi、sGC激动剂和ERA延缓CKD进展的疗效仍需更大规模临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: People with chronic kidney disease (CKD) are at a high risk of heart disease and end-stage kidney disease. This review describes how new medications, such as glucagon-like peptide-1 receptor agonists (GLP1RA), aldosterone synthase inhibitors (ASi), soluble guanylate cyclase (sGC) and endothelin receptor antagonists (ERA), can lower heart-kidney risk in people with CKD. GLP1RA are already recommended for managing blood sugar in people with CKD and type 2 diabetes and have been shown to lower the risk of developing end-stage kidney disease. GLP1RA will likely soon be included in clinical guidelines, but further research is needed to understand how these medications protect the kidneys. ASi are another new medication that lower the protein found in urine. Larger trials are being done to see how well these medications work in slowing CKD. Lastly, both sGC agonists and ERAs have been shown to relax blood vessels to improve blood flow in the kidney, and reduce the amount of protein found in urine, both of which are critical to protecting kidneys. Larger clinical trials are being done to see if these medications prevent CKD from getting worse. In summary, this review describes the new and promising treatments for CKD. These therapies hold the potential to slow kidney disease and improve the wellbeing of patients. Further research of these new treatments is important for improving CKD care. ABSTRACT: Despite recent advancements in the treatment of chronic kidney disease (CKD), identifying novel therapies beyond guideline-directed therapies that reduce residual cardiorenal risk remains imperative. In this review, we highlight the clinical evidence supporting emerging therapies for CKD, including glucagon-like peptide-1 receptor agonists (GLP1RA) and other incretin-based therapies, aldosterone synthase inhibitors (ASI), endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) agonists and anti-inflammatory drugs. Long-acting GLP1RA are already recommended for glycemic control in patients with CKD and type 2 diabetes and the large, dedicated kidney outcome trial FLOW was recently stopped early for efficacy. Emerging clinical trial evidence supports the concept that ASI also provide additional benefit on top of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, which remain a cornerstone of CKD treatment. Next, we consider the use of sGC agonists, which target nitric oxide bioavailability and thereby reduce albuminuria. Finally, we explore the therapeutic potential of ERA, which act through hemodynamic and anti-fibrotic mechanisms, thereby addressing a common final pathway in the development of CKD. Accordingly, our review highlights the changing therapeutic landscape for CKD with promising agents to further prevent the progression of kidney disease.
引用
- Nardone M, Yau K, Kugathasan L, et al. Upcoming drug targets for kidney protective effects in chronic kidney disease. Nephrol Dial Transplant. 2025. PMID: 39907540. doi:10.1093/ndt/gfae216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。